RedHill Biopharma Ltd., known by its ticker symbol RDHL, is a specialty biopharmaceutical company. It was founded in 2009 and is headquartered in Tel Aviv, Israel, with a US office in Raleigh, North Carolina. The biopharmaceutical company operates internationally and is listed on both the NASDAQ Global Market and the Tel Aviv Stock Exchange.
The main aim of RedHill Biopharma Ltd. is the development, manufacturing, and commercialization of proprietary drugs for several therapeutic indications. They focus primarily on diseases with high unmet medical needs, particularly in the fields of gastrointestinal and infectious diseases. The company's strategic approach to drug development is to bring novel, small molecule compounds to the market by leveraging its development capabilities and expertise in these areas.
RedHill Biopharma Ltd's rich and expanding portfolio includes multiple late-stage clinical programs. This portfolio covers numerous drugs, some of which are wholly owned and some of which are collaborations with other pharmaceutical companies. Some of its key products include Talicia (RHB-105) for the treatment of Helicobacter pylori infection, Movantik for opioid-induced constipation, and RHB-204 for pulmonary non-tuberculous mycobacteria (NTM) infections.
Talicia is the first and only FDA-approved rifabutin-based therapy for H. pylori infection. The approval of Talicia by the FDA in 2019, marked a significant milestone for RedHill as it positioned the company at the front line of fighting antibiotic resistance.
RedHill’s strategy also includes collaborations, acquisitions, and in-licensing in the discovery, development, and, in some cases, the commercialization stages of its therapeutic candidates. The company works closely with hospitals, university research centers, and other institutions around the world to accelerate its drug development initiatives and deliver innovative treatments to patients.
In addition to its focus on gastrointestinal and infectious diseases, RedHill has also been active in responding to the COVID-19 pandemic. They are currently advancing OPAGANIB (Yeliva, ABC294640), a first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with anticancer, anti-viral, and anti-inflammatory activities, in global Phase 2/3 and Phase 2 studies in patients with severe COVID-19 pneumonia.
RedHill Biopharma Ltd. continues to grow steadily, signifying its commitment to research and development in areas where there is a pressing need for new treatments. The range of their pipeline, from early development stages to late-stage clinical programs, illustrates a future-forward approach and commitment to innovation in biopharmaceutical research.